Physician profile
Robin B Bone
NPI 1972563088
$17,946.69
in general payments reported to CMS, 2019-2025
32 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $360 · 2021: $539 · 2022: $600 · 2023: $544 · 2024: $768 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,720 · Honoraria: $2,700 · Food and Beverage: $2,543 · Travel and Lodging: $854 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,720.00 |
| Honoraria | $2,700.00 |
| Food and Beverage | $2,543.39 |
| Travel and Lodging | $854.27 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $14,800.01 | 2021-2025 | |
| Abbvie INC. | $713.96 | 2019-2022 | |
| Exeltis, USA INC. | $451.73 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $312.71 | 2019-2024 | Veozah |
| Sumitomo Pharma America, INC. | $167.83 | 2023-2025 | Myfembree |
| Pfizer INC. | $153.99 | 2019-2023 | |
| Amgen INC. | $140.64 | 2019-2021 | |
| Biogen, INC. | $125.00 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $116.11 | 2021-2022 | |
| Therapeuticsmd, INC. | $97.34 | 2019-2022 | |
| Evofem Biosciences, INC. | $96.58 | 2021-2025 | Phexxi, Solosec, Phexx |
| Biom'Up France Sas | $82.80 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $71.53 | 2022 | |
| Mylan Pharmaceuticals INC. | $64.20 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.23 | 2020-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $54.66 | 2019-2023 | Balcoltra |
| Takeda Pharmaceuticals U.S.A., INC. | $43.59 | 2019-2021 | |
| Millicent US INC | $42.68 | 2020-2023 | Femring, Intrarosa |
| Agile Therapeutics, INC. | $41.01 | 2021 | |
| Ethicon US, LLC | $39.44 | 2022-2025 | Dermabond Prineo |
| Scynexis, INC. | $36.58 | 2022 | |
| Astellas Pharma Global Development | $35.66 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $33.89 | 2022-2023 | Gardasil 9 |
| Mission Pharmacal Company | $32.11 | 2019 | |
| Coopersurgical, INC. | $26.46 | 2019 | |
| Radius Health, INC. | $19.92 | 2019 | |
| Organon LLC | $18.13 | 2021 | |
| Meditrina | $14.61 | 2025 | |
| Medtronic, INC. | $14.39 | 2025 | Ligasure |
| Lupin INC. | $12.72 | 2019 | |
| Becton, Dickinson and Company | $12.54 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Bone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.